SCHEMBL6129084

SCHEMBL6129084

O=[N+]([O-])C(NO)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.42
HDAC1 Q13547 2/20 0.41
HDAC8 Q9BY41 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
LMNA P02545 3/20 0.38
ALDH1A1 P00352 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYP2D6 P10635 1/20 0.37
SRC P12931 1/20 0.37
ACP3 P15309 1/20 0.37
FBP1 P09467 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21219507 0.98 GSR (0.41) GSRHDAC1HDAC8HDAC6HDAC3
SCHEMBL2029476 0.80 MAPT (0.41) GSRHDAC1HDAC8HDAC6HDAC3
SCHEMBL2325620 0.79 AOC3 (0.39) GSRLMNAALDH1A1TDP1NPC1
SCHEMBL27394315 0.79 HTR2A (0.39) GSRLMNAALDH1A1TDP1CYP2D6
SCHEMBL27524142 0.77 ALDH1A1 (0.50) GSRLMNAALDH1A1TDP1
SCHEMBL5677901 0.76 GSR (0.36) GSRLMNAALDH1A1TDP1CYP2D6
SCHEMBL5677907 0.76 EPHX1 (0.40) GSRLMNAALDH1A1TDP1CYP2D6
SCHEMBL513919 0.76 GSR (0.44) GSRLMNAALDH1A1NPC1ADAM17
SCHEMBL8930553 0.76 GSR (0.40) GSRLMNAALDH1A1KMT2AMEN1
SCHEMBL516296 0.73 TGM2 (0.43) LMNAALDH1A1TDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3521319-B1 METHOD FOR LIBERATING SUGAR CHAIN FROM GLYCOPROTEIN AIST (JP) 2024-01-10 EP claimed
US-20050282749-A1 Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes SANOS BIOSCIENCE A/S 2005-12-22 US disclosed
EP-1414486-A2 USE OF GLP-2 IN COMBINATION WITH ANOTHER THERAPEUTIC AGENT IN BONE-RELATED AND NUTRITION-RELATED DISORDERS Osteometer Biotech AS (DK) 2004-05-06 EP disclosed
WO-2002024214-A2 USE OF GLP -2 IN COMBINATION WITH ANOTHER THERAPEUTIC AGENT IN BONE-RELATED AND NUTRITION-RELATED DISORDERS OSTEOMETER BIOTECH A/S (DK) 2002-03-28 WO disclosed
US-5112741-A Reaction with an amine ENZYMATICS, INC. (US) 1992-05-12 US disclosed